Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Heron Therapeutics (Nasdaq: HRTX) will report third quarter 2025 financial results on Tuesday, November 4, 2025, and will host a conference call and live webcast at 8:30 a.m. ET to discuss results and recent business highlights.
Participants can join by phone via a registration link that provides dial-in details; callers are encouraged to dial in 15 minutes early. The webcast will be available in the Investor Relations section at www.herontx.com. An archive of the teleconference and webcast will be available on the website for 60 days after the call.
Heron Therapeutics (Nasdaq: HRTX) riferirà risultati finanziari del terzo trimestre 2025 martedì 4 novembre 2025 e ospiterà una conference call e una webcast in diretta alle 8:30 a.m. ET per discutere i risultati e i recenti punti salienti dell’attività.
I partecipanti possono partecipare telefonicamente tramite un link di registrazione che fornisce i dettagli per la chiamata; si consiglia ai partecipanti di collegarsi 15 minuti prima. Il webcast sarà disponibile nella sezione Relazioni con gli Investitori su www.herontx.com. Un archivio della teleconferenza e della webcast sarà disponibile sul sito per 60 giorni dopo la chiamata.
Heron Therapeutics (Nasdaq: HRTX) informará los resultados financieros del tercer trimestre de 2025 el martes 4 de noviembre de 2025 y organizará una llamada de conferencia y webcast en vivo a las 8:30 a.m. ET para discutir los resultados y los aspectos más destacados recientes de la empresa.
Los participantes pueden unirse por teléfono mediante un enlace de registro que proporciona los detalles de marcación; se recomienda a los llamantes marcar 15 minutos antes. El webcast estará disponible en la sección de Relaciones con Inversores en www.herontx.com. Un archivo de la teleconferencia y webcast estará disponible en el sitio web durante 60 días después de la llamada.
Heron Therapeutics (나스닥: HRTX)은 2025년 3분기 재무 실적을 2025년 11월 4일 화요일에 발표하고, 동부 표준시 기준 오전 8시 30분에 결과 및 최근 비즈니스 하이라이트를 논의하기 위한 컨퍼런스 콜 및 라이브 웹캐스트를 개최합니다.
참가자는 전화로 등록 링크를 통해 다이얼인 세부 정보를 제공받아 참여할 수 있으며, 전화 참여자들은 15분 일찍 연결하는 것이 권장됩니다. 웹캐스트는 www.herontx.com의 투자자 관계 섹션에서 이용 가능합니다. 통화의 웹캐스트 및 teleconference의 아카이브는 호출 후 60일 동안 홈페이지에서 이용 가능합니다.
Heron Therapeutics (Nasdaq : HRTX) publiera les résultats financiers du troisième trimestre 2025 mardi 4 novembre 2025 et organisera une conférence téléphonique et une diffusion en direct par webcast à 8h30, heure de l’Est pour discuter des résultats et des points saillants récents de l’activité.
Les participants peuvent rejoindre par téléphone via un lien d’inscription qui fournit les détails de connexion; il est recommandé aux appelants de composer 15 minutes plus tôt. Le webcast sera disponible dans la section Relations investisseurs sur www.herontx.com. Une archive de la téléconférence et du webcast sera disponible sur le site Web pendant 60 jours après l’appel.
Heron Therapeutics (Nasdaq: HRTX) wird am Dienstag, dem 4. November 2025, die Ergebnisse des dritten Quartals 2025 bekannt geben und wird um 8:30 Uhr ET eine Telefonkonferenz und einen Live-Webcast abhalten, um die Ergebnisse und die jüngsten Geschäftshighlights zu diskutieren.
Teilnehmer können telefonisch über einen Registrierungslink teilnehmen, der die Dial-in-Details bereitstellt; Anrufer wird empfohlen, sich 15 Minuten früher einzuwählen. Der Webcast ist im Bereich Investor Relations unter www.herontx.com verfügbar. Ein Archiv der Telekonferenz und des Webcasts wird auf der Website für 60 Tage nach dem Anruf verfügbar sein.
Heron Therapeutics (Nasdaq: HRTX) ستعلن عن النتائج المالية للربع الثالث من 2025 يوم الثلاثاء 4 نوفمبر 2025، وستستضيف مكالمة مؤتمرات وبثاً مباشراً عبر الويب في الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة النتائج وأبرز التطورات الأخيرة في الأعمال.
يمكن للمشاركين الانضمام هاتفياً من خلال رابط التسجيل الذي يوفر تفاصيل الوصول؛ يُفضل على المتصلين الاتصال قبل 15 دقيقة من بدء المكالمة. سيكون البث عبر الويب متاحاً في قسم علاقات المستثمرين على www.herontx.com. وسيكون هناك أرشيف للمكالمة وبث الويب على الموقع لمدة 60 يوماً بعد المكالمة.
Heron Therapeutics（纳斯达克：HRTX） 将于 2025 年 11 月 4 日星期二公布 2025 年第三季度财务业绩，并将于东部时间 上午 8:30 举行电话会议和现场直播网络广播，以讨论业绩和最近的业务亮点。
参与者可以通过提供拨入细节的注册链接通过电话参与；建议来电者在 15 分钟 前拨入。网络广播将在投资者关系部分的 www.herontx.com 提供。
电话会议和网络广播的存档将在呼叫结束后的 60 天 内在该网站提供。
- None.
- None.
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
FAQ
When will Heron Therapeutics (HRTX) report Q3 2025 results and hold the conference call?
How can investors access the Heron Therapeutics (HRTX) November 4, 2025 earnings call?
Is there a recommended time to join the Heron Therapeutics (HRTX) conference call on November 4, 2025?
Will the Heron Therapeutics (HRTX) Q3 2025 webcast be available after the live call?
What topics will Heron Therapeutics (HRTX) cover during the November 4, 2025 call?
Where on the Heron Therapeutics (HRTX) site can I find the webcast and archive for the Q3 2025 call?
